trial

Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia

NCTId NCT00255515
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 85 (actual)
Sponsored by AstraZeneca
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
85 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2005-09
Primary completion
2007-12
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Quetiapineconventional treatment for schizophrenia

Sponsors

AstraZenecaLead Sponsor

Investigators

1
Leif Lindström,Principal Investigator

Sites

15 total
Eskilstuna, SwedenGothenburg, SwedenHisingsbacka, SwedenHuddinge, SwedenJönköping, SwedenLidingö, SwedenLimhamn, SwedenLund, SwedenMalmö, SwedenNorsborg, SwedenNyköping, SwedenStockholm, Sweden

Facts & assertions

4 sourced
Enrollment
85
Phase
PHASE4
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
conventional treatment for schizophrenia
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Leif Lindström,
person